Dose-related nephrotoxicity of carboplatin in children
Authors:
Open Access
- 27 August 1999
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 81 (2) , 336-341
Abstract
This study investigated changes and the time course of these changes in renal function in children following treatment with carboplatin, and identified risk factors for nephrotoxicity. Glomerular and proximal renal tubular function were investigated before and up to 2 years after treatment in 23 children who received carboplatin. The main findings were reduced glomerular filtration rate (GFR), and increased renal tubular loss of magnesium, manifested by a low serum magnesium (S Mg). The mean fall in GFR was 22 ml min–1 1.73 m–2 (P = 0.012), and in S Mg it was 0.17 mmol l–1 (P = 0.0077). No patient had a clinically important reduction in GFR, and only one patient had symptomatic hypomagnesaemia. GFR and S Mg did not change over time after completion of treatment. Cumulative dose (CD) of carboplatin was inversely related to mean S Mg at the end of treatment (P = 0.031), and directly related to the fall in S Mg (P < 0.001). Calculated cumulative area under the plasma concentration versus time curve (AUC) of carboplatin was inversely related to S Mg after treatment (P = 0.004). Dose intensity (DI) of carboplatin was not shown to be related to S Mg following treatment. CD, AUC and DI of carboplatin were not related to GFR, nor change in GFR, after treatment. High CDs of carboplatin may be associated with evidence of renal damage qualitatively similar to but less severe than that caused by cisplatin. GFR and SMg should be carefully monitored when high CDs of carboplatin are used, or if carboplatin is combined with other nephrotoxic chemotherapy.Keywords
This publication has 38 references indexed in Scilit:
- An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children.Archives of Disease in Childhood, 1996
- Acute renal failure in high dose carboplatin chemotherapyMedical and Pediatric Oncology, 1995
- Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: A report from the neuroblastoma group of the spanish society of pediatric oncologyMedical and Pediatric Oncology, 1995
- Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: Experience of the Brazilian Wilms' tumor study groupMedical and Pediatric Oncology, 1994
- What is the place of carboplatin in paediatric oncology?European Journal of Cancer, 1994
- Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastomaEuropean Journal of Cancer, 1992
- Toxicity of single-day high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastomaEuropean Journal of Cancer, 1992
- Partial reversibility of cisplatin nephrotoxicity in childrenThe Journal of Pediatrics, 1991
- Renal toxicity of cisplatin in childrenThe Journal of Pediatrics, 1985
- Cis-diamminedichloroplatinum (II) by 5-day continuous infusion a new dose schedule with minimal toxicityCancer, 1984